Bracco (Germany)

Ultrasound technology is always connected to possible artefacts. Since introduction of ultrasound technology the knowledge of those artefacts is eminent to avoid misinterpretations. It is important to know that with the introduction of new ultrasound technology the possibility of artefacts are rising.Whereas artefacts initially were limited to B-mode sonography, every technological step (colour Doppler sonography, contrast enhanced sonography) comes with a range of new artefacts. This article is written to explain the technological basics of ultrasound artefacts and provide the reader with examples in daily practice and how to avoid them.

Ultrasound contrast agents have substantially extended the clinical value of ultrasound, allowing the assessment of blood flow and distribution in real-time down to microcapillary level. Selective imaging of contrast agent signals requires a contrast-specific imaging mode on the ultrasound scanner, allowing real-time separation of tissue and contrast agent signals. The creation of a contrast image requires a specific interaction between the insonated ultrasound wave and the contrast agent microbubbles, leading to persistent oscillation of the bubbles. Several technical and procedural parameters have a significant influence on the quality of CEUS images and should be controlled carefully to obtain good image quality and a reliable diagnosis. Achieving the proper balance between the respective parameters is a matter of technical knowledge and experience. Appropriate training and education should be mandatory for every investigator performing CEUS examinations.

Der Ultraschall ist das meist zuerst und am häufigsten eingesetzte Verfahren zur Bildgebung der Leber. So wundert es nicht, dass oft zufällig Leberläsionen mit dieser Bildgebungsmethode entdeckt werden. Insbesondere zur Charakterisierung dieser inzidentellen fokalen Leberläsionen hat der Ultraschall durch kontrastmittelspezifische Techniken in den letzten Jahren deutlich an diagnostischer Aussagekraft gewonnen.

Methods: 15 healthy volunteers (15 men, 26–36 years) underwent two abdominal MR exams with renal perfusion measurements and renal MRA: one exam at 1.5T (Avanto, Siemens) and one on a 3.0T (Tim Trio, Siemens). The MRA (spatial resolution 1.5T: 1.0×0.8×1.0mm3, 3.0T: 0.9×0.8×0.9mm3) was acquired using parallel imaging factor 3 after the administration of Gd-BOPTA (Multihance, Bracco) For the perfusion measurements, a saturation-recovery TurboFLASH acquiring 4 (1.5T) slices per second or 5 (3.0T, parallel imaging factor 2) with a spatial resolution of 2.9×2.3×8mm3 was used after the administration of 7ml of Gd-BOPTA at 4ml/s. Image quality was rated by two radiologists in consensus on a 4 point ordinal scale (4-very good –1 poor). Signal-to-noise ratio (SNR) was measured. On an offline workstation perfusion parameters were calculated on a pixel-by-pixel basis: mean transit time (MTT), time to signal peak (TTP), maximal signal intensity (MSI), maximal upslope of the curve (MUS). T-tests were used for statistical analysis.

To investigate the dependence of semiquantitative renal perfusion parameters on the acquisition technique and field strength used. After intravenous injection of 7-mL Gd-chelates, high-temporal-resolution turbo fast low-angle shot (TurboFLASH) renal perfusion measurements were performed on eight healthy volunteers at 1.5T and another eight healthy volunteers at 3.0T. Another eight healthy volunteers were examined at 3.0T using time-resolved echo-shared angiographic technique (TREAT) after bolus administration of 7-mL Gd-chelates with a temporal resolution of 1.4 seconds. Analysis of the first-pass perfusion data yielded the following semiquantitative renal perfusion indices: mean transit time (MTT), time to peak (TTP), maximal upslope (MUS), and maximal signal intensity (MSI). MTT and TTP did not show significant differences between the different techniques. MSI and MUS were significantly (P < or = 0.002) higher with TREAT (591.1 a.u./second and 103.5 a.u./second) than with TurboFLASH at both field strengths (1.5T: 400.5 a.u./second and 65.4 a.u./second; 3.0T: 362.2 a.u./second and 68.7 a.u./second). Semiquantitative renal perfusion measurements are feasible with time-resolved echo-shared sequences and TurboFLASH techniques. While MTT and TTP appear to be independent of the technique and field strength applied, MUS and MSI are higher with TREAT.

Contrast-enhanced magnetic resonance imaging (CE-MRI) is a valuable technique for the diagnosis of liver diseases. As gadocoletic acid trisodium salt (B22956/1), a new contrast agent showing high biliary excretion, may be potentially advantageous in hepatobiliary imaging, the aim of the study was to investigate the molecular mechanisms of hepatic transport of the B22956 ion in a cellular model of hepatic tumor. B22956 ion uptake was measured in tumoral (HepG2) and nontumoral (Chang liver) hepatic cell lines. Absolute quantitative real-time reverse transcriptase (RT)-polymerase chain reaction (PCR) analyses, using cloned PCR products as standards, were performed on total RNA of both cell lines and normal liver to evaluate the transcription of 12 transport genes: SLCO1A2, SLCO2B1, SLCO1B1, SLCO3A1, SLCO4A1, SLCO1B3, SLC22A7, SLC22A8, SLC22A1, SLC10A1, SLC15A1, and SLC15A2. B22956 transport was more efficient in Chang liver than in HepG2 cells and was inhibited by cholecystokinin-8, a specific substrate of OATP1B3. Real-time RT-PCR analyses revealed different transcription profiles in the tumoral and nontumoral cell lines. Compared with normal liver, the expression of SLCO1B1, SLCO3A1, and SLCO1B3 was greatly repressed in HepG2 cells, whereas SLCO2B1, SLC22A7, and SLC22A8 expression was either maintained or increased. On the contrary, in Chang liver cells, SLC22A7 and SLC22A8 genes were undetectable, whereas the expression of SLCO3A1, SLCO4A1, and SLCO1B3 was similar to normal liver. Transport studies and gene expression analyses indicated that B22956 ion is a good substrate to the liver-specific OATP1B3, reported to be poorly expressed or absent in human liver tumors. Therefore, B22956 may be helpful in detecting hepatic neoplastic lesions by CE-MRI.

The objective of this study was to evaluate the value of a color-coded automated signal intensity curve software package for contrast-enhanced magnetic resonance mammography (CE-MRM) in patients with suspected breast cancer. Thirty-six women with suspected breast cancer based on mammographic and sonographic examinations were preoperatively evaluated on CE-MRM. CE-MRM was performed on a 1.5-T magnet using a 2D Flash dynamic T1-weighted sequence. A dosage of 0.1 mmol/kg of Gd-BOPTA was administered at a flow rate of 2 mL/s followed by 10 mL of saline. Images were analyzed with the new software package and separately with a standard display method. Statistical comparison was performed of the confidence for lesion detection and characterization with the 2 methods and of the diagnostic accuracy for characterization compared with histopathologic findings. At pathology, 54 malignant lesions and 14 benign lesions were evaluated. All 68 (100%) lesions were detected with both methods and good correlation with histopathologic specimens was obtained. Confidence for both detection and characterization was significantly (P < or = 0.025) better with the color-coded method, although no difference (P > 0.05) between the methods was noted in terms of the sensitivity, specificity, and overall accuracy for lesion characterization. Excellent agreement between the 2 methods was noted for both the determination of lesion size (kappa = 0.77) and determination of SI/T curves (kappa = 0.85). The novel color-coded signal intensity curve software allows lesions to be visualized as false color maps that correspond to conventional signal intensity time curves. Detection and characterization of breast lesions with this method is quick and easily interpretable.

Intestinal hyperaemia is a sign of active disease in the inflamed intestine which can be detected by Doppler sonography. This technique, however, can be jeopardized by tissue motion artefacts (peristalsis), and intramural enteric vessel perfusion may be below the detection threshold. Visualisation of vessels by Contrast Harmonic Imaging (CHI) at a low Mechanical Index (low MI) is not restricted by the limitations mentioned above. Contrast Harmonic Imaging at low MI of the intestinal wall has not yet been described with high frequency probes. We therefore evaluated the validity of this method for detecting hyperaemia of the intestinal wall. CHI at low MI was performed with a 7.5 MHz ultrasound probe in 12 patients with signs of an inflamed intestine. The contrast agent BR 1 (4.8 ml) was injected intravenously. Contrast enhancement was quantified by analysing gray scale values before and after injection of BR 1 in regions of interest within the submucosal layer. At about 15 sec. after injection of BR 1, arterial inflow of the contrast agent with visualisation of the feeding mesenteric vessels and intense contrast of the submucosal lamina could be observed. An increase of the gray scale values within the ROI after contrast enhancement was detected in all patients. We have shown that CHI at low MI is technically feasible for the demonstration of increased intestinal perfusion in inflammatory bowel disease by using a high resolution ultrasound probe. One possible method of quantifying the contrast enhancement is the gray scale analysis of pixels in defined regions of interest within the submucosal layer.

To assess the vascular contrasting properties of a new MR contrast agent (gadobenate dimeglumine [Gd-BOPTA]), which presents higher relaxivity because of reversible, weak protein interaction, and, to compare these properties with a standard gadolinium agent. Two phase I trials compared intraindividually: (A) the vascular contrasting properties of Gd-BOPTA at three doses (0.0125, 0.05, and 0.2 mmol/kg body weight) and two flow rates (0.5 and 2.0 mL/s) in 10 volunteers; and (B) 0.1 mmol/kg body weight doses of Gd-BOPTA and Gd-DTPA at 2.0 mL/s using a modified magnetic resonance angiography (MRA) sequence with a temporal resolution of 1 s/f. Quantitative (ROI analysis) and fully blinded qualitative (reader review) assessment of images was performed. A dose of 0.2 mmol/kg resulted in higher maximum intensities, longer median peak widths, and larger areas under the curve than did the lower doses (0.0125 mmol/kg and 0.05 mmol/kg). In the intraindividual comparison, Gd-BOPTA demonstrated significantly better vascular enhancement characteristics in terms of signal peak duration (p < 0.05), maximum signal intensity (p < 0.05), and area under the enhancement curve (p < 0.01). The multireader assessment for overall vascular contrast preferred Gd-BOPTA at p < 0.03. Gd-BOPTA was shown to exhibit preferential and different vascular enhancement properties as compared with Gd-DTPA for MRA.

This study was conducted to determine the efficacy and safety of four different doses of gadobenate dimeglumine for contrast-enhanced three-dimensional MR angiography of the abdominal aorta and renal arteries. Ninety-four patients with suspected abnormality of the abdominal aorta or renal arteries underwent unenhanced three-dimensional gradient-recalled echo time-of-flight MR angiography and contrast-enhanced MR angiography after the IV injection of one of four doses of gadobenate dimeglumine (0.025, 0.05, 0.1, and 0.2 mmol/kg of body weight). Efficacy was assessed on-site and by two blinded off-site reviewers in terms of change in total diagnostic quality score and diagnostic quality score per vessel segment from baseline unenhanced time-of-flight MR angiography to contrast-enhanced MR angiography. Secondary efficacy end points included lesion count and level of confidence in lesion characterization. Safety assessments comprised adverse event monitoring, physical evaluation, vital signs, ECG, and laboratory investigations. A significant change in the total diagnostic quality score from unenhanced to contrast-enhanced MR angiography was observed at all doses. The change increased with increased dose, plateauing at the 0.1 mmol/kg dose level. More patients with lesions detected and increased reviewer confidence for lesion characterization were noted on contrast-enhanced MR angiography compared with unenhanced MR angiography, although no dose-related trends were observed. All doses were well tolerated, and no significant changes in safety parameters were observed. Gadobenate dimeglumine is an effective and safe agent for contrast-enhanced MR angiography of the abdominal aorta and renal arteries. A dose of 0.1 mmol/kg of body weight appears to be the most suitable.